[To learn English]
Biopharmaceutical company Sanofi will stop a Phase 3 trial of its drug riliprubart for a rare neurological condition after an interim analysis of the study found it unlikely to provide sufficient efficacy.
In the MOBILIZE study, the drug was being tested for chronic inflammatory demyelinating polyneuropathy in patients whose condition resisted standard treatments.
生物制药公司赛诺菲将停止其药物 riliprubart 针对一种罕见神经系统疾病的III期试验，此前一项中期分析发现该药不太可能达到足够的疗效。
在 MOBILIZE 研究中，该药被测试用于治疗慢性炎症性脱髓鞘性多发性神经病，患者对此前的标准治疗已产生耐药性。
LearnEnglish Leave a remark